- Home
- OFS vs NSPR Comparison
OFS vs NSPR Comparison
Compare OFS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- NSPR
- Stock Information
- Founded
- OFS 2001
- NSPR 2005
- Country
- OFS United States
- NSPR United States
- Employees
- OFS N/A
- NSPR N/A
- Industry
- OFS Finance/Investors Services
- NSPR Medical/Dental Instruments
- Sector
- OFS Finance
- NSPR Health Care
- Exchange
- OFS Nasdaq
- NSPR Nasdaq
- Market Cap
- OFS 117.0M
- NSPR 99.7M
- IPO Year
- OFS 2012
- NSPR N/A
- Fundamental
- Price
- OFS $7.15
- NSPR $2.26
- Analyst Decision
- OFS
- NSPR Strong Buy
- Analyst Count
- OFS 0
- NSPR 2
- Target Price
- OFS N/A
- NSPR $4.50
- AVG Volume (30 Days)
- OFS 67.0K
- NSPR 54.5K
- Earning Date
- OFS 11-06-2025
- NSPR 11-04-2025
- Dividend Yield
- OFS 19.06%
- NSPR N/A
- EPS Growth
- OFS N/A
- NSPR N/A
- EPS
- OFS 0.76
- NSPR N/A
- Revenue
- OFS $43,337,000.00
- NSPR $7,066,000.00
- Revenue This Year
- OFS N/A
- NSPR $7.48
- Revenue Next Year
- OFS N/A
- NSPR $104.39
- P/E Ratio
- OFS $9.33
- NSPR N/A
- Revenue Growth
- OFS N/A
- NSPR 7.60
- 52 Week Low
- OFS $6.80
- NSPR $1.99
- 52 Week High
- OFS $9.80
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- OFS 35.46
- NSPR 32.33
- Support Level
- OFS $6.93
- NSPR $2.20
- Resistance Level
- OFS $7.19
- NSPR $2.37
- Average True Range (ATR)
- OFS 0.19
- NSPR 0.09
- MACD
- OFS 0.02
- NSPR -0.02
- Stochastic Oscillator
- OFS 37.79
- NSPR 11.68
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.